Investor Relations

Corporate Profile

We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Recent News

January 13, 2020

Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

SAN FRANCISCO , Jan. 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-st...

January 8, 2020

Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

SAN FRANCISCO , Jan. 8, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...

December 16, 2019

Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

SAN FRANCISCO , Dec. 16, 2019 /PRNewswire/ --  Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-s...

November 13, 2019

Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-s...

November 12, 2019

Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results

SAN FRANCISCO , Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-s...

November 11, 2019

Akero Chief Development Officer Kitty Yale Named to 2019 Fierce Pharma “Fiercest Women in Life Sciences”

Akero Therapeutics is thrilled to announce that its chief development officer Kitty Yale has been re...